MEDX
Exchange-traded product on NASDAQ (US)
- Type
- Exchange-traded product
- Share class
- —
- Status
- listed
- ISIN
- —
- Currency
- —
- Represents the company
- No
Holdings as of Jun 30, 2026
The full portfolio as of the quarter end Jun 30, 2026, from the fund's report to the SEC (Form N-PORT, filed Aug 26, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of Mar 31, 2026.
33 lines, 30 linked, weights sum to 101.83% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | LLY US5324571083 | Equity | 2,936 | −141 | 18.46% | $ 3.522M |
|
US BANK MMDA - USBGFS 7
|
USBGFS7 | Money market | 1,752,681.13 | −68,123.34 | 9.19% | $ 1.753M |
| AbbVie Inc | ABBV US00287Y1091 | Equity | 6,712 | −322 | 8.85% | $ 1.689M |
| Novartis AG | NVS US66987V1098 | Equity | 8,388 | −403 | 6.89% | $ 1.315M |
| Johnson & Johnson | JNJ US4781601046 | Equity | 4,200 | −201 | 5.59% | $ 1.067M |
| Alkermes PLC | ALKS IE00B56GVS15 | Equity | 20,132 | −967 | 5.53% | $ 1.055M |
| AstraZeneca PLC | AZN GB0009895292 | Equity | 5,015 | −241 | 4.98% | $ 950.944K |
| Ionis Pharmaceuticals Inc | IONS US4622221004 | Equity | 10,904 | −524 | 4.53% | $ 864.578K |
| Bristol-Myers Squibb Co | BMY US1101221083 | Equity | 14,644 | −704 | 4.42% | $ 843.787K |
| Merck & Co Inc | MRK US58933Y1055 | Equity | 5,872 | −282 | 3.96% | $ 754.552K |
| Amgen Inc | AMGN US0311621009 | Equity | 2,062 | −99 | 3.91% | $ 746.691K |
| Alnylam Pharmaceuticals Inc | ALNY US02043Q1076 | Equity | 2,168 | −104 | 3.42% | $ 652.633K |
| Biogen Inc | BIIB US09062X1037 | Equity | 2,726 | −131 | 3.09% | $ 588.98K |
| Pfizer Inc | PFE US7170811035 | Equity | 22,648 | −1,088 | 2.86% | $ 545.364K |
| GSK PLC | GSK US37733W2044 | Equity | 9,846 | −473 | 2.71% | $ 516.127K |
| CRISPR Therapeutics AG | CRSP CH0334081137 | Equity | 9,228 | −443 | 2.64% | $ 503.295K |
| Regeneron Pharmaceuticals Inc | REGN US75886F1075 | Equity | 630 | −30 | 2.06% | $ 392.83K |
| Beam Therapeutics Inc | BEAM US07373V1052 | Equity | 8,388 | −403 | 1.51% | $ 287.876K |
| Galectin Therapeutics Inc | GALT US3632252025 | Equity | 46,968 | −2,258 | 1.14% | $ 217.932K |
| Intellia Therapeutics Inc | NTLA US45826J1051 | Equity | 12,584 | −604 | 1.12% | $ 212.921K |
|
Sandoz Group AG
|
SDZNY US7999261008 | Equity | 1,680 | −80 | 0.80% | $ 152.023K |
| Replimune Group Inc | REPL US76029N1063 | Equity | 12,584 | −604 | 0.73% | $ 139.305K |
| Vanda Pharmaceuticals Inc | VNDA US9216591084 | Equity | 22,648 | −1,088 | 0.73% | $ 138.606K |
| Haleon PLC | HLN US4055521003 | Equity | 12,309 | −591 | 0.60% | $ 114.843K |
| Lantern Pharma Inc | LTRN US51654W1018 | Equity | 25,164 | −1,209 | 0.55% | $ 104.934K |
| Editas Medicine Inc | EDIT US28106W1036 | Equity | 27,680 | −1,330 | 0.47% | $ 89.683K |
| GE HealthCare Technologies Inc | GEHC US36266G1076 | Equity | 840 | −40 | 0.28% | $ 53.768K |
| Bicycle Therapeutics PLC | BCYC US0887861088 | Equity | 12,584 | −604 | 0.28% | $ 53.356K |
| Viatris Inc | VTRS US92556V1061 | Equity | 3,122 | −150 | 0.26% | $ 49.577K |
| Allogene Therapeutics Inc | ALLO US0197701065 | Equity | 16,776 | −806 | 0.18% | $ 34.894K |
| Pacific Biosciences of Califor | PACB US69404D1081 | Equity | 10,068 | −483 | 0.09% | $ 16.914K |
| Decoy Therapeutics Inc | DCOY US79400X6022 | Equity | 20.75 | 0 | 0.00% | $ 149.19 |
|
Pathos AI Inc
|
2368714D | Equity | 23,992 | 0 | 0.00% | $ 0.00 |